Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antidepressant Drugs: MAOIs and Other Agents

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...

Sedatives and Hypnotics Drugs: Miscellaneous Agents

Sedatives and Hypnotics Drugs: Miscellaneous Agents

Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...

Antipsychotic Drugs: Typical and Atypical Agents

Antipsychotic Drugs: Typical and Atypical Agents

Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...

Drugs Affecting Neurotransmitter Release or Uptake

Drugs Affecting Neurotransmitter Release or Uptake

Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of the aromatic...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Structure-property relationships of benzyl-substituted urea-based ligands with Phe-Phe linker targeting prostate-specific membrane antigen labeled with gallium-68.

Bioorganic chemistry·2026

Same author

A mild and atom-efficient four-component cascade strategy for the construction of biologically relevant 4-hydroxyquinolin-2(1<i>H</i>)-one derivatives.

Beilstein journal of organic chemistry·2026

Same author

A novel, covalent broad-spectrum inhibitor targeting human coronavirus M<sup>pro</sup>.

Nature communications·2025

Same author

Coculture-Based Screening Revealed Selective Cytostatic Effects of Pyrazol-Azepinoindoles.

ChemMedChem·2025

Same author

Antiviral Susceptibility of Influenza A(H5N1) Clade 2.3.2.1c and 2.3.4.4b Viruses from Humans, 2023-2024.

Emerging infectious diseases·2025

Same author

Small molecule ATM inhibitors as potential cancer therapy: a patent review (2003-present).

Expert opinion on therapeutic patents·2024

Search research articles

Related Experiment Video

Updated: Jun 10, 2026

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

5-hydroxytryptamine subtype 6 receptor modulators: a patent survey.

Alexandre V Ivachtchenko¹, Yan A Ivanenkov, Sergey E Tkachenko

¹ChemDiv, Inc., 6605 Nancy Ridge Drive, San Diego, CA 92121, USA. av@chemdiv.com

Expert Opinion on Therapeutic Patents

|August 19, 2010

Summary

Patent analysis reveals 5-HT(6) receptor ligands show significant pharmaceutical potential. These compounds are promising drug candidates for treating neurological disorders like Alzheimer's disease.

Related Experiment Videos

Last Updated: Jun 10, 2026

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

Area of Science:

Pharmacology
Medicinal Chemistry
Intellectual Property

Background:

G-protein coupled receptors (GPCRs), particularly 5-HT receptors, are crucial biological targets with significant clinical relevance.
The 5-HT(6) receptor has garnered substantial attention due to its diverse cellular functions and potential modulation by inverse agonists.

Purpose of the Study:

To analyze patent literature concerning 5-HT(6) receptor ligands.
To understand the evolution and trends in the patent landscape of 5-HT(6) therapeutics.

Main Methods:

Comprehensive search of key patent collections focusing on 5-HT(6) ligands.
Analysis of patent specifications, geographic distribution, trends, and patent holders.

Main Results:

Identification of small molecule compounds targeting 5-HT(6) receptors in clinical trials and on the market.
Detailed overview of the patent landscape, including geographical spread and key players.

Conclusions:

5-HT(6) targeted compounds represent viable drug candidates for neuropathological disorders.
Potential applications include treatments for Alzheimer's disease and Huntington's disease.